MedImmune Inc. received long-awaited news late Tuesday afternoon as the FDA approved FluMist, a nasally delivered product that has ridden a rocky road throughout the regulatory review process. (BioWorld Today)

Questcor Raises $5M To Fund $18.2M Purchase Of Nascobal

June 18, 2003

By Aaron Lorenzo

Boston Life Sciences Plans Another Altropane Phase III

June 18, 2003

By Aaron Lorenzo

Boston Life Sciences Plans Another Altropane Phase III

June 18, 2003

By Aaron Lorenzo

MedImmune's Intranasal Vaccine FluMist Receives FDA Approval

June 18, 2003

By Aaron Lorenzo

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment
BioWorld Science
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...